Using the latest TTM figures, Biogen shows a gross margin of 74%, an operating margin of 10.1%, an EBITDA margin of 18.5%, and a net margin of 8.3%. Operating margin had the largest decline, falling by 7.9 percentage points, while the other available margins also weakened.
Over the last 3 years, Biogen recorded average margins of 75.25% gross, 16.08% operating, 23.29% EBITDA, and 13.75% net. The current gross, operating, EBITDA, and net margins are all below their three-year averages.
Year over year, gross, operating, EBITDA, and net margins all declined, with operating margin showing the largest decrease at 7.9 percentage points.
Over the last 3 years, the average gross margin for Biogen was 75.25%. Biogen's current gross margin is 74% and is 1.3 percentage points below its three-year average. Biogen's gross margin ranged from a low of 74% in Jun 2026 to a high of 76.1% in Dec 2024.
Across the last 3 years, Biogen's operating margin stood at 16.08%. The current operating margin stands at 10.1%, 6 percentage points below its three-year average. Operating margin was highest at 19.8% in Sep 2024 and lowest at 10.1% in Jun 2026.
Biogen recorded an average EBITDA margin of 23.29% across the last 3 years. Compared with its three-year average, Biogen's current EBITDA margin is 18.5% and is 4.8 percentage points below its three-year average. The highest EBITDA margin for Biogen was 27.3% in Dec 2024, while the lowest was 18.2% in Dec 2023.
Across the last 3 years, Biogen's net margin stood at 13.75%. The current net margin stands at 8.3%, 5.5 percentage points below its three-year average. Net margin was highest at 16.9% in Dec 2024 and lowest at 8.3% in Jun 2026.
Biogen's gross margin of 74% is higher than the Healthcare sector, the industry and its peers average. In comparison with the Healthcare sector average of 68.4%, Biogen's gross margin is 8% higher.
As of Jun 30, 2026, BIIB has a gross margin of 74%.
For the period ending Jun 30, 2026, BIIB recorded an operating margin of 10.1%.
As of Jun 30, 2026, BIIB has an EBITDA margin of 18.5%.
The current net margin for BIIB is 8.3% as of Jun 30, 2026.
Over the last 3 years, Biogen's margins averaged 75.3% gross, 16.1% operating, 23.3% EBITDA, and 13.8% net.
In the last 5 years, the highest margins reported by BIIB were 80.8% gross in Dec 2021, 36.4% operating in Mar 2023, 42.6% EBITDA in Sep 2022, and 31% net in Mar 2023.
Over this 5-year history, Biogen's margins fell as low as 74% gross in Jun 2026, 10.1% operating in Jun 2026, 18.2% EBITDA in Dec 2023, and 8.3% net in Jun 2026.